Contributor.

Mark Mallon
AstraZeneca

Mark Mallon is executive vice president, international, at AstraZeneca. He is responsible for the growth and performance of AstraZeneca’s commercial businesses in various regions, including Asia Pacific, Russia, Latin America, the Middle East and Africa. Since joining AstraZeneca in 1994, he has held multiple senior sales and marketing roles, including regional vice president for Asia Pacific, president of AstraZeneca’s Chinese and Italian subsidiaries, chief operating officer of AstraZeneca’s Japanese subsidiary and vice president of AstraZeneca’s U.S. gastrointestinal and respiratory businesses. He has served as a member of the board of directors for Christiana Care, the largest hospital system in Delaware, and an executive committee member for the R&D-based Pharmaceutical Association Committee, the China industry association for innovative pharmaceutical companies. He holds a degree in chemical engineering from the University of Pennsylvania and a master’s in business administration in marketing and finance from the Wharton School of Business, Pennsylvania.

Articles by Mark Mallon

  • Mark Mallon

    Turning Global Targets into Action

    For the first time, the global health community is being called to act against the rise of NCDs, the root cause of 38 million of the 56 million deaths in 2012. What may come as a shock, given that NCDs are generally thought of as diseases of affluence, is that Africa as a whole is poised to bear the bulk of the NCD burden in the coming years.

    Categories
    Health Care
    Tags
    public-private partnerships